Companies / BOC Sciences / ocrelizumab
BOC Sciences

ocrelizumab | BOC Sciences

Ocrelizumab is an anti-CD20 monoclonal antibody developed by Genentech to treat relapsing and primary progressive forms of multiple sclerosis (MS).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.